Xultophy Approval History
- FDA approved: Yes (First approved November 21st, 2016)
- Brand name: Xultophy
- Generic name: insulin degludec and liraglutide
- Dosage form: Injection
- Previous name: IDegLira
- Company: Novo Nordisk
- Treatment for: Diabetes, Type 2
Xultophy 100/3.6 (insulin degludec and liraglutide) is a fixed-ratio combination of the long-acting basal insulin analog, insulin degludec (Tresiba), and the a glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide (Victoza), indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
FDA approval of Xultophy 100/3.6 was based on efficacy and safety data from three Phase 3 clinical trials involving 1,393 adults with type 2 diabetes. Results showed that patients who were inadequately controlled on liraglutide, basal insulin, or insulin glargine, all achieved reductions in A1C after conversion to Xultophy therapy.
Xultophy 100/3.6 is administered subcutaneously in the thigh, upper arm or abdomen via a pre-filled, pen injector once daily at same time each day, with or without food. Common side effects include stuffy or runny nose, sore throat, upper respiratory tract infection, increased blood levels of lipase, nausea, diarrhea, and headache.
Development History and FDA Approval Process for Xultophy
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.